Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 16/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464137 | 0.89 | GRIK1 (0.77) | GRIK1RXFP1KDRMEN1MAPT | |
| SCHEMBL9268782 | 0.86 | RXFP1 (0.78) | ALDH1A1RXFP1MAPTRAB9A | |
| SCHEMBL1463217 | 0.86 | GRIK1 (1.00) | GRIK1RXFP1KDRMEN1MAPT | |
| SCHEMBL17664319 | 0.85 | KMT2A (0.82) | GRIK1ALDH1A1RXFP1KDRMEN1 | |
| SCHEMBL6430550 | 0.83 | GRIK1 (0.69) | GRIK1RXFP1KDRMEN1MAPT | |
| SCHEMBL23831539 | 0.83 | MEN1 (0.64) | GRIK1ALDH1A1MEN1MAPTHTT | |
| SCHEMBL16127721 | 0.82 | GRIK1 (0.75) | GRIK1RXFP1KDRMEN1MAPT | |
| SCHEMBL966454 | 0.81 | ALDH1A1 (1.00) | GRIK1ALDH1A1KDRMEN1MAPT | |
| SCHEMBL5597699 | 0.81 | KMT2A (0.90) | GRIK1ALDH1A1KDRMEN1MAPT | |
| SCHEMBL30101230 | 0.81 | KMT2A (0.90) | GRIK1ALDH1A1KDRMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | GRIK1 655/4885ALDH1A1 327/4885RXFP1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.